Cargando…
Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?
BACKGROUND: The causality of overactive bladder syndrome (OAB) is still not fully understood. Several studies indicate a significant increase of prostaglandin E2 (PGE2) in patients with OAB. However, in order to clarify whether these compounds can help to objectify the clinical diagnosis, further st...
Autores principales: | Hegele, Axel, Knippschild, Sonja, Frohme, Carsten, Hänze, Jörg, Olbert, Peter, Hofmann, Rainer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230352/ https://www.ncbi.nlm.nih.gov/pubmed/25370343 http://dx.doi.org/10.1186/1471-2490-14-85 |
Ejemplares similares
-
Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells
por: Hänze, Jörg, et al.
Publicado: (2013) -
Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016) -
TOT Approach in stress urinary incontinence (SUI) – outcome in obese female
por: Frohme, Carsten, et al.
Publicado: (2014) -
Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
por: Cohen, Brian L., et al.
Publicado: (2009) -
The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)